<div id="readability-page-1">Phase 2 trial results have revealed that efdoralprin alfa showed superior performance compared to standard-of-care augmentation therapy in increasing fAAT levels in patients with AATD. The data highlights the efficacy of efdoralprin alfa in achieving higher levels of fAAT.</div>

512010

159837

159102

<p>Phase 2 trial results have revealed that efdoralprin alfa showed superior performance compared to standard-of-care augmentation therapy in increasing fAAT levels in patients with AATD. The data highlights the efficacy of efdoralprin alfa in achieving higher levels of fAAT.</p>

Unusual Whales

E Fund CSI 300 Health Care ETF

E Fund CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

VG Health

Guotai CSI Bio-medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Health Care Select Sector SPDR

Invesco Nasdaq Biotechnology ETF

ChinaAMC CSI Biotechnology Theme ETF

BlackRock, Inc.

iShares US Pharma

iShares Global Healthcare

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Tianhong CNI BIOMEDICINE ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

ChinaAMC SSE STAR Biology and Medicine ETF

Ark Genomic Revolution ETF

China Merchants CSI Biotechnology Theme ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD